Archive · 1 Oct 2025
Market Roundup: RBI, Company Updates, and Sector Developments
The stock market saw some movement after the central bank kept interest rates the same.
Several companies made important moves: Pfizer won a break from some tariffs, while Zydus extended a deal's end date.
Lupin got approval for a new medicine, and Man Industries was penalized.
Also, RITES partnered with Etihad Rail.
Waaree Energies opened a factory, and CMS Info Systems plans to cut some jobs.
Several other companies also had news, showing many changes in the business world.
Sensex and Nifty rebounded after the RBI held the repo rate steady.
Pfizer secured a reprieve from pharmaceutical tariffs.
Zydus Lifesciences extended the closing date for an acquisition.
Lupin received US FDA approval for a drug.
Man Industries faced penalties from SEBI.
- Who
- Pfizer Inc., Zydus Lifesciences, New India Assurance, Lupin, Man Industries, RITES, Waaree Energies, CMS Info Systems, and numerous other companies.
- What
- Various companies announced updates, including regulatory approvals, partnerships, and financial actions.
- When
- October 01, 2025, with specific deadlines and effective dates mentioned.
- Where
- Across various locations, including India, the US, and other international markets.
- Why
- These updates reflect market activity, expansions, financial adjustments, and regulatory compliance.
- Sensex/Nifty
- Rebounded after RBI held the repo rate steady.
- Pfizer
- Secured a 3-year reprieve from pharmaceutical tariffs.
- Zydus Lifesciences
- Extended acquisition closing date to December 31, 2025.
- New India Assurance
- Received a GST demand of Rs 2,379 Crores.
- Lupin
- Received US FDA approval for Rivaroxaban Oral Suspension.
- Man Industries
- SEBI penalized for non-consolidation of financials.
- RITES
- Signed a pact with Etihad Rail.
- Waaree Energies
- Established 950 MW solar module line facility in Gujarat.
- CMS Info Systems
- Planning 10% workforce reduction to boost productivity.
